550 related articles for article (PubMed ID: 33491917)
1. Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
Ayton S; Portbury S; Kalinowski P; Agarwal P; Diouf I; Schneider JA; Morris MC; Bush AI
Alzheimers Dement; 2021 Jul; 17(7):1244-1256. PubMed ID: 33491917
[TBL] [Abstract][Full Text] [Related]
2. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
[TBL] [Abstract][Full Text] [Related]
3. Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.
Faraji P; Kühn H; Ahmadian S
J Mol Neurosci; 2024 Jul; 74(3):62. PubMed ID: 38958788
[TBL] [Abstract][Full Text] [Related]
4. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
5. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.
Shinohara M; Fujioka S; Murray ME; Wojtas A; Baker M; Rovelet-Lecrux A; Rademakers R; Das P; Parisi JE; Graff-Radford NR; Petersen RC; Dickson DW; Bu G
Brain; 2014 May; 137(Pt 5):1533-49. PubMed ID: 24625695
[TBL] [Abstract][Full Text] [Related]
6. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.
Thaker U; McDonagh AM; Iwatsubo T; Lendon CL; Pickering-Brown SM; Mann DM
Neuropathol Appl Neurobiol; 2003 Feb; 29(1):35-44. PubMed ID: 12581338
[TBL] [Abstract][Full Text] [Related]
7. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
8. Is Cerebrospinal Fluid Superoxide Dismutase 1 a Biomarker of Tau But Not Amyloid-Induced Neurodegeneration in Alzheimer's Disease?
McLimans KE; Clark BE; Plagman A; Pappas C; Klinedinst B; Anatharam V; Kanthasamy A; Willette AA
Antioxid Redox Signal; 2019 Sep; 31(8):572-578. PubMed ID: 31088292
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology.
Kehoe PG; Wong S; Al Mulhim N; Palmer LE; Miners JS
Alzheimers Res Ther; 2016 Nov; 8(1):50. PubMed ID: 27884212
[TBL] [Abstract][Full Text] [Related]
10. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease.
Leoni V
Clin Chem Lab Med; 2011 Mar; 49(3):375-83. PubMed ID: 21388338
[TBL] [Abstract][Full Text] [Related]
11. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy.
Belaidi AA; Masaldan S; Southon A; Kalinowski P; Acevedo K; Appukuttan AT; Portbury S; Lei P; Agarwal P; Leurgans SE; Schneider J; Conrad M; Bush AI; Ayton S
Mol Psychiatry; 2024 Feb; 29(2):211-220. PubMed ID: 35484240
[TBL] [Abstract][Full Text] [Related]
13. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
[TBL] [Abstract][Full Text] [Related]
14. A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction With N-terminal Amyloid Precursor Protein, Reduces β-Amyloid-Associated Pathology, and Improves Cognition.
Sawmiller D; Habib A; Hou H; Mori T; Fan A; Tian J; Zeng J; Giunta B; Sanberg PR; Mattson MP; Tan J
Biol Psychiatry; 2019 Aug; 86(3):208-220. PubMed ID: 31208706
[TBL] [Abstract][Full Text] [Related]
15. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
16. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
17. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau.
Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL;
JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024
[TBL] [Abstract][Full Text] [Related]
18. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
[TBL] [Abstract][Full Text] [Related]
19. An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
Caselli RJ; Knopman DS; Bu G
Alzheimers Dement; 2020 Nov; 16(11):1582-1590. PubMed ID: 32588983
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Review of Alzheimer's Association with Related Proteins: Pathological Role and Therapeutic Significance.
Kumar D; Sharma A; Sharma L
Curr Neuropharmacol; 2020; 18(8):674-695. PubMed ID: 32172687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
